Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX » 05:13
05/22/20
05/22
05:13
05/22/20
05:13
BMRN

BioMarin

$94.83 /

+0.75 (+0.80%)

, CPRI

Capri Holdings

$15.09 /

+1.1 (+7.86%)

, ETRN

Equitrans Midstream

$7.88 /

-0.115 (-1.44%)

, FMC

FMC Corporation

$91.82 /

-1.14 (-1.23%)

, GLNG

Golar LNG

$6.75 /

-0.16 (-2.32%)

, KEY

KeyCorp

$10.71 /

-0.03 (-0.28%)

, LHX

L3Harris Technologies

$183.97 /

+4.97 (+2.78%)

, LKQ

LKQ Corp.

$25.51 /

+ (+0.00%)

, BX

Blackstone

$53.65 /

-0.655 (-1.21%)

, MSI

Motorola Solutions

$137.08 /

-1.46 (-1.05%)

, RIO

Rio Tinto

$51.80 /

-0.59 (-1.13%)

, RTX

Raytheon Technologies

$60.10 /

+2.32 (+4.02%)

Analysts at Jefferies…

Analysts at Jefferies made changes to the firm's Franchise Picks list, which is comprised of their highest-conviction Buy-rated ideas. The analysts removed Capri Holdings (CPR), Equitrans Midstream (ETRN), FMC Corporation (FMC), Golar LNG (GLNG), KeyCorp (KEY), L3Harris Technologies (LHX) and LKQ Corp. (LKQ). The analysts added six ideas they believe are "poised to outperform:" BioMarin (BMRN), Blackstone (BX), Motorola Solutions (MSI), Rio Tinto (RIO), Raytheon Technologies (RTX) and TJX (TJX).

ShowHide Related Items >><<
RTX Raytheon Technologies
$60.10 /

+2.32 (+4.02%)

RIO Rio Tinto
$51.80 /

-0.59 (-1.13%)

MSI Motorola Solutions
$137.08 /

-1.46 (-1.05%)

LKQ LKQ Corp.
$25.51 /

+ (+0.00%)

LHX L3Harris Technologies
$183.97 /

+4.97 (+2.78%)

KEY KeyCorp
$10.71 /

-0.03 (-0.28%)

GLNG Golar LNG
$6.75 /

-0.16 (-2.32%)

FMC FMC Corporation
$91.82 /

-1.14 (-1.23%)

ETRN Equitrans Midstream
$7.88 /

-0.115 (-1.44%)

CPRI Capri Holdings
$15.09 /

+1.1 (+7.86%)

BX Blackstone
$53.65 /

-0.655 (-1.21%)

BMRN BioMarin
$94.83 /

+0.75 (+0.80%)

BMRN BioMarin
$94.83 /

+0.75 (+0.80%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
CPRI Capri Holdings
$15.09 /

+1.1 (+7.86%)

05/18/20
Fly Intel: Top five analyst downgrades
05/18/20 Piper Sandler
Capri Holdings downgraded to Neutral from Overweight at Piper Sandler
04/28/20 BTIG
Capri Holdings initiated with a Neutral at BTIG
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
ETRN Equitrans Midstream
$7.88 /

-0.115 (-1.44%)

05/19/20 RBC Capital
EQT Midstream Partners price target raised to $21 from $15 at RBC Capital
04/27/20 Wells Fargo
Equitrans Midstream double upgraded to Overweight at Wells Fargo
04/27/20 Wells Fargo
Equitrans Midstream upgraded to Overweight from Underweight at Wells Fargo
01/07/20 Wells Fargo
Equitrans Midstream downgraded to Underweight at Wells Fargo
FMC FMC Corporation
$91.82 /

-1.14 (-1.23%)

05/07/20 KeyBanc
FMC Corporation price target raised to $108 from $93 at KeyBanc
05/07/20 Citi
FMC Corporation price target raised to $114 from $107 at Citi
04/06/20 SunTrust
FMC Corporation price target lowered to $106 from $125 at SunTrust
03/26/20 KeyBanc
KeyBanc bullish on FMC Corporation, initiates with an Overweight
GLNG Golar LNG
$6.75 /

-0.16 (-2.32%)

04/08/20 B. Riley FBR
Golar LNG price target lowered to $13 from $21 at B. Riley FBR
03/09/20 DNB Markets
Golar LNG downgraded to Hold from Buy at DNB Markets
02/04/20 Goldman Sachs
Golar LNG upgraded to Neutral from Sell at Goldman Sachs
12/11/19
Fly Intel: Top five analyst initiations
KEY KeyCorp
$10.71 /

-0.03 (-0.28%)

05/04/20 UBS
Wells Fargo, PNC Financial cut to Sell, Keycorp cut to Neutral at UBS
05/04/20 UBS
KeyCorp downgraded to Neutral from Buy at UBS
04/17/20 BofA
KeyCorp downgraded to Neutral from Buy at BofA
04/17/20 BofA
KeyCorp downgraded to Neutral from Buy at BofA
LHX L3Harris Technologies
$183.97 /

+4.97 (+2.78%)

05/20/20 RBC Capital
RBC starts 'best-in-class' L3Harris Technologies at Outperform
05/20/20 RBC Capital
L3Harris Technologies initiated with an Outperform at RBC Capital
05/19/20 Seaport Global
Seaport starts L3Harris with Buy, names top pick in Defense
05/19/20 Seaport Global
L3Harris Technologies initiated with a Buy at Seaport Global
LKQ LKQ Corp.
$25.51 /

+ (+0.00%)

11/01/19 SunTrust
LKQ Corp. price target raised to $40 from $35 at SunTrust
11/01/19 Jefferies
LKQ Corp. price target raised to $40 from $37 at Jefferies
09/13/19 Jefferies
LKQ Corp. activist stake a 'meaningful positive,' says Jefferies
08/14/19
LKQ Corp.management to meet with Stephens
BX Blackstone
$53.65 /

-0.655 (-1.21%)

04/24/20 Citi
Blackstone price target raised to $57.50 from $53.50 at Citi
04/15/20 Wells Fargo
Blackstone price target lowered to $62 from $70 at Wells Fargo
04/14/20 Nomura Instinet
Alnylam risks not absolved with Blackstone deal, says Nomura Instinet
03/19/20 Citi
Blackstone upgraded to Buy from Neutral at Citi
MSI Motorola Solutions
$137.08 /

-1.46 (-1.05%)

05/08/20
Fly Intel: Top five analyst downgrades
05/08/20 MKM Partners
Motorola Solutions price target lowered to $150 from $192 at MKM Partners
05/08/20 Cowen
Motorola Solutions weakness a buying opportunity, says Cowen
05/08/20 Credit Suisse
Motorola Solutions price target lowered to $161 from $196 at Credit Suisse
RIO Rio Tinto
$51.80 /

-0.59 (-1.13%)

05/20/20 UBS
Rio Tinto price target lowered to 4,100 GBp from 4,250 GBp at UBS
05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 JPMorgan
Rio Tinto price target lowered to 4,560 GBp from 4,730 GBp at JPMorgan
04/30/20 JPMorgan
Rio Tinto price target lowered to 4,730 GBp from 4,870 GBp at JPMorgan
RTX Raytheon Technologies
$60.10 /

+2.32 (+4.02%)

05/20/20 RBC Capital
RBC starts 'significantly undervalued' Raytheon Technologies at Outperform
05/20/20 RBC Capital
Raytheon Technologies initiated with an Outperform at RBC Capital
04/20/20 Credit Suisse
Raytheon Technologies price target lowered to $81 from $101.45 at Credit Suisse
04/15/20 JPMorgan
Raytheon Technologies downgraded to Neutral upon assumption at JPMorgan
RTX Raytheon Technologies
$60.10 /

+2.32 (+4.02%)

MSI Motorola Solutions
$137.08 /

-1.46 (-1.05%)

LKQ LKQ Corp.
$25.51 /

+ (+0.00%)

LHX L3Harris Technologies
$183.97 /

+4.97 (+2.78%)

KEY KeyCorp
$10.71 /

-0.03 (-0.28%)

GLNG Golar LNG
$6.75 /

-0.16 (-2.32%)

FMC FMC Corporation
$91.82 /

-1.14 (-1.23%)

ETRN Equitrans Midstream
$7.88 /

-0.115 (-1.44%)

CPRI Capri Holdings
$15.09 /

+1.1 (+7.86%)

BX Blackstone
$53.65 /

-0.655 (-1.21%)

BMRN BioMarin
$94.83 /

+0.75 (+0.80%)

RTX Raytheon Technologies
$60.10 /

+2.32 (+4.02%)

RIO Rio Tinto
$51.80 /

-0.59 (-1.13%)

MSI Motorola Solutions
$137.08 /

-1.46 (-1.05%)

LHX L3Harris Technologies
$183.97 /

+4.97 (+2.78%)

KEY KeyCorp
$10.71 /

-0.03 (-0.28%)

FMC FMC Corporation
$91.82 /

-1.14 (-1.23%)

BX Blackstone
$53.65 /

-0.655 (-1.21%)

RTX Raytheon Technologies
$60.10 /

+2.32 (+4.02%)

RIO Rio Tinto
$51.80 /

-0.59 (-1.13%)

MSI Motorola Solutions
$137.08 /

-1.46 (-1.05%)

LKQ LKQ Corp.
$25.51 /

+ (+0.00%)

LHX L3Harris Technologies
$183.97 /

+4.97 (+2.78%)

KEY KeyCorp
$10.71 /

-0.03 (-0.28%)

FMC FMC Corporation
$91.82 /

-1.14 (-1.23%)

ETRN Equitrans Midstream
$7.88 /

-0.115 (-1.44%)

CPRI Capri Holdings
$15.09 /

+1.1 (+7.86%)

BX Blackstone
$53.65 /

-0.655 (-1.21%)

BMRN BioMarin
$94.83 /

+0.75 (+0.80%)

RTX Raytheon Technologies
$60.10 /

+2.32 (+4.02%)

RIO Rio Tinto
$51.80 /

-0.59 (-1.13%)

LKQ LKQ Corp.
$25.51 /

+ (+0.00%)

KEY KeyCorp
$10.71 /

-0.03 (-0.28%)

GLNG Golar LNG
$6.75 /

-0.16 (-2.32%)

FMC FMC Corporation
$91.82 /

-1.14 (-1.23%)

ETRN Equitrans Midstream
$7.88 /

-0.115 (-1.44%)

CPRI Capri Holdings
$15.09 /

+1.1 (+7.86%)

BX Blackstone
$53.65 /

-0.655 (-1.21%)

BMRN BioMarin
$94.83 /

+0.75 (+0.80%)

Thursday
Conference/Events
Ionis Pharmaceuticals management to meet virtually with Oppenheimer » 04:55
05/21/20
05/21
04:55
05/21/20
04:55
IONS

Ionis Pharmaceuticals

$54.30 /

+0.75 (+1.40%)

Virtual Meeting to be…

Virtual Meeting to be held on May 21 hosted by Oppenheimer.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$54.30 /

+0.75 (+1.40%)

IONS Ionis Pharmaceuticals
$54.30 /

+0.75 (+1.40%)

05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
IONS Ionis Pharmaceuticals
$54.30 /

+0.75 (+1.40%)

IONS Ionis Pharmaceuticals
$54.30 /

+0.75 (+1.40%)

Wednesday
Conference/Events
Ionis Pharmaceuticals management to meet virtually with Oppenheimer » 09:24
05/20/20
05/20
09:24
05/20/20
09:24
IONS

Ionis Pharmaceuticals

$53.55 /

-1.48 (-2.69%)

Virtual Meeting to be…

Virtual Meeting to be held on May 21 hosted by Oppenheimer.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$53.55 /

-1.48 (-2.69%)

IONS Ionis Pharmaceuticals
$53.55 /

-1.48 (-2.69%)

05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
IONS Ionis Pharmaceuticals
$53.55 /

-1.48 (-2.69%)

IONS Ionis Pharmaceuticals
$53.55 /

-1.48 (-2.69%)

Hot Stocks
Fate Therapeutics announces FDA clearance of IND application for FT538 » 08:15
05/20/20
05/20
08:15
05/20/20
08:15
FATE

Fate Therapeutics

$28.85 /

-0.76 (-2.57%)

Fate Therapeutics…

Fate Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. FT538 is an off-the-shelf natural killer cell cancer immunotherapy that is derived from a clonal master induced pluripotent stem cell line engineered with three functional components to enhance innate immunity: a novel high-affinity, non-cleavable CD16 Fc receptor; an IL-15/IL-15 receptor fusion; and the elimination of CD38 expression. The Company plans to initiate clinical investigation of three once-weekly doses of FT538 as a monotherapy in acute myeloid leukemia and in combination with daratumumab, a CD38-directed monoclonal antibody therapy, for the treatment of multiple myeloma. The three functional components of FT538 are designed to boost the innate immune response in cancer patients, where endogenous NK cells are typically diminished in both number and function due to prior treatment regimens and tumor suppressive mechanisms. In preclinical studies, FT538 has shown superior NK cell effector function, as compared to endogenous NK cells, with the potential to confer significant anti-tumor activity to patients through multiple mechanisms of action including: Expression of the hnCD16 Fc receptor, which improves antibody-dependent cellular cytotoxicity, a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells; Expression of the IL-15RF cytokine complex, which promotes NK cell survival and persistence and induces trans-activation of endogenous NK cells and CD8 T cells; and Elimination of CD38 expression, which enhances innate effector function, including granzyme and perforin levels and resistance to oxidative stress, and prevents anti-CD38 antibody-mediated NK cell death. The first-in-human, multi-center, dose-escalation Phase 1 clinical trial of FT538 is designed to determine the maximum tolerated dose of three once-weekly doses of FT538 in up to 105 adult patients across four dose cohorts. The study will assess two treatment regimens: Regimen A as a monotherapy in patients with relapsed / refractory AML; and Regimen B in combination with daratumumab, an FDA-approved anti-CD38 monoclonal antibody, in patients with relapsed / refractory multiple myeloma who have failed at least two lines of therapy. In addition, the Company may initiate a third treatment regimen in combination with elotuzumab, an FDA-approved anti-SLAMF7 monoclonal antibody, in patients with relapsed / refractory multiple myeloma who have failed at least two lines of therapy starting at one dose level below the MTD of Regimen B. For all regimens, multiple indication- or dose-specific dose-expansion cohorts of up to 15 patients per cohort may be enrolled to further evaluate the clinical activity of FT538. FT538 is the fourth off-the-shelf, iPSC-derived NK cell product candidate from the Company's proprietary iPSC product platform cleared for clinical investigation by the FDA. The Company has initiated clinical manufacture of FT538 at its GMP facility in San Diego, CA.

ShowHide Related Items >><<
FATE Fate Therapeutics
$28.85 /

-0.76 (-2.57%)

FATE Fate Therapeutics
$28.85 /

-0.76 (-2.57%)

05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
FATE Fate Therapeutics
$28.85 /

-0.76 (-2.57%)

FATE Fate Therapeutics
$28.85 /

-0.76 (-2.57%)

Hot Stocks
Applied Genetic announces publication of preclinical data on XLRP program » 07:10
05/20/20
05/20
07:10
05/20/20
07:10
AGTC

Applied Genetic

$4.19 /

-0.01 (-0.24%)

Applied Genetic…

Applied Genetic Technologies Corporation announced the publication of positive preclinical data that provide the foundation for the vector and starting dose used in its ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene. The data, which demonstrate that the company's proprietary AAV vector and engineered RPGR constructs were well tolerated and had beneficial effects on markers of disease in a canine model of XLRP, were published online in Human Gene Therapy. The DNA sequence encoding the full length RPGR protein contains repetitive sequences that can lead to instability during vector engineering and manufacturing. One approach to overcoming this challenge is to remove the repetitive sequence, which results in a truncated RPGR protein. Another approach is to change the repetitive sequence to reduce instability while producing the full-length RPGR protein. The publication reports data from dose-ranging studies utilizing AGTC's proprietary rAAV2tYF capsid to deliver either a truncated RPGR DNA sequence or an RPGR sequence encoding full-length RPGR protein optimized for stability in a canine model of XLRP. Following subretinal injection, both transgenes showed similar levels of efficacy as assessed by fundus reflectivity, outer nuclear layer thickness, correction of opsin mislocalization and length of cone inner segments at all doses tested; in some cases, hRPRGco showed superior efficacy. Both vectors were generally well tolerated, with retinal detachment and inflammation observed only in the high dose group. The results supported the selection of rAAV2tYF-GRK1-hRPGRco as the optimized vector to advance to clinical trials and informed the dosing schedule for the company's ongoing Phase 1/2 XLRP clinical trial. In January 2020, AGTC announced positive interim six-month data from its ongoing Phase 1/2 clinical program in XLRP. The results show that four of eight evaluable patients treated centrally with its product candidate demonstrated durable improvement in visual sensitivity six months after dosing. All patients demonstrated a favorable safety profile for the XLRP candidate, with no dose-limiting inflammatory responses observed and no secondary inflammatory responses requiring re-administration of steroids in any patients. Preliminary data also showed that all nine centrally dosed patients had stable or improving visual acuity at the six-month time point, a result that has not been reported by others.

ShowHide Related Items >><<
AGTC Applied Genetic
$4.19 /

-0.01 (-0.24%)

AGTC Applied Genetic
$4.19 /

-0.01 (-0.24%)

02/12/20 Roth Capital
Applied Genetic in position to execute after cash raise, says Roth Capital
01/28/20
Fly Intel: Top five analyst initiations
01/27/20 Roth Capital
Applied Genetic initiated with a Buy at Roth Capital
01/09/20 BMO Capital
Applied Genetic price target raised to $16 from $9 at BMO Capital
AGTC Applied Genetic
$4.19 /

-0.01 (-0.24%)

Conference/Events
RBC Capital to hold a virtual conference » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
ADUS

Addus HomeCare

$89.04 /

-0.89 (-0.99%)

, HOOK

Hookipa Pharma

$9.27 /

-0.88 (-8.67%)

, KPTI

Karyopharm

$17.68 /

-0.97 (-5.20%)

, UHS

Universal Health

$101.01 /

+0.55 (+0.55%)

, ENTA

Enanta

$54.33 /

-3.25 (-5.64%)

, REGN

Regeneron

$557.61 /

-1.76 (-0.31%)

, ARAV

Aravive

$12.27 /

-0.31 (-2.46%)

, IMGN

ImmunoGen

$4.62 /

-0.14 (-2.94%)

, HCA

HCA Healthcare

$103.94 /

-1.63 (-1.54%)

, PFE

Pfizer

$37.68 /

-0.4 (-1.05%)

, BCEL

Atreca

$18.06 /

-0.69 (-3.68%)

, JAZZ

Jazz Pharmaceuticals

$113.07 /

-3.23 (-2.78%)

, OVID

Ovid Therapeutics

$4.46 /

+0.29 (+6.95%)

, ACAD

Acadia

$51.02 /

-1.05 (-2.02%)

, BMRN

BioMarin

$93.88 /

-1.46 (-1.53%)

, EHTH

eHealth

$124.65 /

-2.38 (-1.87%)

, EXEL

Exelixis

$24.87 /

-0.79 (-3.08%)

, INO

Inovio

$14.56 /

+0.41 (+2.90%)

, SPRT

Support.com

$1.25 /

-0.01 (-0.79%)

, CYH

Community Health

$3.11 /

-0.05 (-1.58%)

, INCY

Incyte

$94.92 /

-1.58 (-1.64%)

, AGIO

Agios Pharmaceuticals

$47.89 /

-0.93 (-1.90%)

, EGRX

Eagle Pharmaceuticals

$53.24 /

-1.26 (-2.31%)

, IGMS

IGM Biosciences

$52.75 /

-2.66 (-4.80%)

, AIMT

Aimmune

$16.55 /

-0.92 (-5.27%)

, VRCA

Verrica Pharmaceuticals

$10.11 /

-0.62 (-5.78%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$101.01 /

+0.55 (+0.55%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$54.33 /

-3.25 (-5.64%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$557.61 /

-1.76 (-0.31%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
ARAV Aravive
$12.27 /

-0.31 (-2.46%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$37.68 /

-0.4 (-1.05%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.06 /

-0.69 (-3.68%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$51.02 /

-1.05 (-2.02%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$124.65 /

-2.38 (-1.87%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.56 /

+0.41 (+2.90%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.25 /

-0.01 (-0.79%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$94.92 /

-1.58 (-1.64%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

Conference/Events
Autolus Therapeutics management to meet virtually with William Blair » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
AUTL

Autolus Therapeutics

$10.98 /

+0.19 (+1.76%)

Virtual Meeting to be…

Virtual Meeting to be held on May 20 hosted by William Blair.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$10.98 /

+0.19 (+1.76%)

AUTL Autolus Therapeutics
$10.98 /

+0.19 (+1.76%)

04/22/20 Mizuho
Mizuho starts Autolus Therapeutics with Buy rating, $18 target
04/21/20 Mizuho
Autolus Therapeutics initiated with a Buy at Mizuho
02/18/20 H.C. Wainwright
Now the time to get long Autolus Therapeutics, says H.C. Wainwright
09/23/19 Needham
Autolus Therapeutics initiated with a Buy at Needham
AUTL Autolus Therapeutics
$10.98 /

+0.19 (+1.76%)

Tuesday
Hot Stocks
Privately-held Galecto names Amit Munshi as new chairman, 'strengthens board' » 17:06
05/19/20
05/19
17:06
05/19/20
17:06
ARNA

Arena Pharmaceuticals

$52.34 /

-1.01 (-1.89%)

, ICPT

Intercept

$87.09 /

+0.96 (+1.11%)

Galecto announced that…

Galecto announced that its board has appointed Amit Munshi as its new chairman. Galecto also announced the appointment of David Shapiro MD, the former Chief Medical Officer of Intercept Pharmaceuticals (ICPT), to its board. Amit Munshi has 30 years of international experience in private and public companies in biotechnology, pharmaceuticals and medical technologies. He is currently CEO of San Diego-based Arena Pharmaceuticals (ARNA) and replaces Magnus Persson, who will continue to be available to Galecto as an adviser and a board observer. "We are delighted to welcome Amit and David to Galecto. Amit has demonstrated outstanding leadership skills and ability to commercialize medicines, grow businesses and deliver impressive returns to investors over 30 years in the healthcare industry. David's long and successful medical experience, particularly in the development of fibrosis treatments, will be an important source of advice and guidance to further advance and expand our pipeline. Together, their experience will prove invaluable as Galecto continues to pursue its ambitious targets, including moving the promising galectin-3 inhibitor GB0139 towards market for treating idiopathic pulmonary fibrosis and further developing our exciting pipeline in fibrosis and cancer," said Hans Schambye, CEO of Galecto.

ShowHide Related Items >><<
ICPT Intercept
$87.09 /

+0.96 (+1.11%)

ARNA Arena Pharmaceuticals
$52.34 /

-1.01 (-1.89%)

ARNA Arena Pharmaceuticals
$52.34 /

-1.01 (-1.89%)

05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
03/31/20 Guggenheim
Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod
ICPT Intercept
$87.09 /

+0.96 (+1.11%)

05/12/20 Citi
Intercept downgraded to Neutral from Buy at Citi
05/12/20 Baird
Intercept competitor trial failure a positive, says at Baird
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
ICPT Intercept
$87.09 /

+0.96 (+1.11%)

ARNA Arena Pharmaceuticals
$52.34 /

-1.01 (-1.89%)

ICPT Intercept
$87.09 /

+0.96 (+1.11%)

ICPT Intercept
$87.09 /

+0.96 (+1.11%)

ARNA Arena Pharmaceuticals
$52.34 /

-1.01 (-1.89%)

ICPT Intercept
$87.09 /

+0.96 (+1.11%)

Conference/Events
BioMarin participates in a conference call hosted by Wolfe Research » 13:55
05/19/20
05/19
13:55
05/19/20
13:55
BMRN

BioMarin

$94.28 /

-1.06 (-1.11%)

Wolfe Research Biotech…

Wolfe Research Biotech & Specialty Pharma Analyst Tewari holds a conference call with CEO Bienaime and President of R&D Fuchs on May 19 at 3 pm.

ShowHide Related Items >><<
BMRN BioMarin
$94.28 /

-1.06 (-1.11%)

BMRN BioMarin
$94.28 /

-1.06 (-1.11%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
BMRN BioMarin
$94.28 /

-1.06 (-1.11%)

BMRN BioMarin
$94.28 /

-1.06 (-1.11%)

BMRN BioMarin
$94.28 /

-1.06 (-1.11%)

Conference/Events
RBC Capital to hold a virtual conference » 08:45
05/19/20
05/19
08:45
05/19/20
08:45
ADUS

Addus HomeCare

$89.93 /

+5.99 (+7.14%)

, HOOK

Hookipa Pharma

$10.15 /

+0.78 (+8.32%)

, KPTI

Karyopharm

$18.65 /

-0.4 (-2.10%)

, UHS

Universal Health

$100.46 /

+7.86 (+8.49%)

, ENTA

Enanta

$57.58 /

+2.25 (+4.07%)

, REGN

Regeneron

$559.37 /

-16.71 (-2.90%)

, ARAV

Aravive

$12.58 /

+0.11 (+0.88%)

, IMGN

ImmunoGen

$4.76 /

+0.33 (+7.45%)

, HCA

HCA Healthcare

$105.57 /

+6.83 (+6.92%)

, PFE

Pfizer

$38.08 /

+0.31 (+0.82%)

, BCEL

Atreca

$18.75 /

-0.44 (-2.29%)

, JAZZ

Jazz Pharmaceuticals

$116.30 /

+4.79 (+4.30%)

, OVID

Ovid Therapeutics

$4.17 /

+0.09 (+2.21%)

, ACAD

Acadia

$52.07 /

+1.23 (+2.42%)

, BMRN

BioMarin

$95.34 /

+1.595 (+1.70%)

, EHTH

eHealth

$127.03 /

+9.13 (+7.74%)

, EXEL

Exelixis

$25.66 /

-0.07 (-0.27%)

, INO

Inovio

$14.15 /

+0.73 (+5.44%)

, SPRT

Support.com

$1.26 /

+0.06 (+5.00%)

, CYH

Community Health

$3.16 /

+0.435 (+15.99%)

, INCY

Incyte

$96.50 /

+0.37 (+0.38%)

, AGIO

Agios Pharmaceuticals

$48.82 /

+2.38 (+5.12%)

, EGRX

Eagle Pharmaceuticals

$54.50 /

+1.74 (+3.30%)

, IGMS

IGM Biosciences

$55.41 /

-3.59 (-6.08%)

, AIMT

Aimmune

$17.47 /

+1.1 (+6.72%)

, VRCA

Verrica Pharmaceuticals

$10.73 /

+0.47 (+4.58%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$100.46 /

+7.86 (+8.49%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$57.58 /

+2.25 (+4.07%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$559.37 /

-16.71 (-2.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
ARAV Aravive
$12.58 /

+0.11 (+0.88%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$38.08 /

+0.31 (+0.82%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.75 /

-0.44 (-2.29%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$52.07 /

+1.23 (+2.42%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$127.03 /

+9.13 (+7.74%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.15 /

+0.73 (+5.44%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.26 /

+0.06 (+5.00%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$96.50 /

+0.37 (+0.38%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.